NEW YORK--(BUSINESS WIRE)--Over the past few years, the strategic importance of China to the global pharmaceutical marketplace has become increasingly clearer. Multinational interest and investment in China’s pharmaceutical industry is at an all-time high and competition is heating up. Companies are looking to China not only for outsourcing opportunities anymore, they are setting up major R&D facilities and striking licensing and partnership deals with local Chinese biotechs. But what strategies are working best? What companies are best positioned to benefit from China’s economic growth?
